Introduction
For· several years I and my research group have been interested in the coordination chemistry of metal ions in biological systems and the extension of this chemistry into the preparation of new sequestering agents for both ferric ion·and actinide(IV) ions. While it may not be obvious why the synthesis of metal-ion-specific complexing agents for iron in the +3 oxidation state and plutonium in the +4 oxidation state should be related, that is in fact a central thesis of our approach to the actinide coordination chemistry problem. I will describe in this paper the train of thought that has led to a number of compounds that 2 we have prepared with the idea that these could be either used themselves or the precursors of compound that could be used in ameleriorating the environmental problems presented by plutonium.
As a statement of the problem, it is clear that whether or not it is used as a part of a nuclear power program, plutonium is a major byproduct of nuclear power reactions. The treatment and storage of the nuclear waste from power reactions remains a serious problem which has become in many countries a matter of substantial public concern. Because of its relative abundance and long half life, 239 Pu is a major environmental hazard of long-term waste after the first 100 years of decay.
addition, the biological properties of plutonium make it a particular hazard once human contamination has occurred.
In
In this paper we will address a few of the following questions: 
How is plutonium transported once incorporated in higher animals?
What chemical reagents presently are used in the treatment of . plutonium contamination in human beings?
How can we design better complexing agents given the answers to these and related questions?
In Table I are some hydrolysis and dissolution kinetics data for plutonium and its polymeric hydroxides. These data (from Ref. in blood plasma decreases by a factor of 2 during the first ten hours.
Very little of this plutonium is subsequently excreted by the animal {approximately 90% is retained). A large fraction of the plutonium (IV) is complexed by transferrin, the serum protein used to transport iron in higher animals. Like the coordination of iron(III), binding of Pu(IV) requires bicarbonate anion. Formation of the Pu(IV) complex is blocked by prior coordination of ferric ion and transferrin-bound Pu(IV) can be replaced by Fe(III), indicating that both are bound at the same site.
The Pu(IV)-transferrin complex can be dissociated by excess citrate at pH 7.5. It is the Pu(IV) transferrin complex which acts as the transfer agents in carrying Pu(IV) from the blood to its eventual deposition sites such as bone marrow, bone surface and the liver. In cells of organs such as the liver, Pu(IV) eventually is concentrated in iron storage sites such as the protein ferritin. The ferritin complex of plutonium is highly stable.
In contrast, the problems posed· by americium are quite different because of the uniform presence of americium only in the trivalent state.
This makes for much more rapid transfer and relatively more rapid exctetion of americium. It also makes the design of a metal-ion-specific complexing agent for americium a very different problem from that posed by plutonium. We should further note that the required properties of specific sequestering agents include not only a high bondiDg constant for the metal ion to be sequestered but, equally important, a low affinity for most other metal ions. When one examines the properties of biological metal ion complexing agents it is found that their specificity is usually quite high and can generally be broken up into three requirements.
First, the coordination number and geometry most favorable for the metal ion is achieved. Second, the cavity formed by the ligand exactly matches the size of the metal ion. Third, the electronic properties of the ligand atom and the metal match. In the case of iron(III) tfle siderophore ligands are hexadentate and capable of achieving an octahedral coordination in which the cavity size is just that of high-spin iron(III).
The ligating oxygen atoms are strongly basic and compliment the high Lewis acidity of the hard ferric ion. 6 .
The siderophores are a good example of metal-ion specific complexing agents produced by living systems. These are low-molecular-weight complexing agents which are produced by bacteria, molds, yeast and other microbes to obtain the iron which is an essential element for microbial growth. These compounds fonn very stable six-coordination complexes of
high-spin Fe(III). The iron binding chara~teristics of the siderophores . are summarized in Figure 1 . The specific example chosen is that of ferric enterobactin, which is produced by enteric bacteria such as~ coli.
Notice that the cylic triester backbone of enterobactin simply acts as a template to which are appended three catechol functional groups such that a hexadentate, octahedral cavi:ty is formed.
Synthetic Iron(III) Chelating Agents Modeled After Enterobactin
The structure of enterobactin itself and two other representative siderophores are shown in Figure 2 . These three compounds are three prototypes for the architecture of synthetic sequestering agents for iron. In the case of enterobactin we have already seen that the structure consists of a cyclic backbone to which are appended three catechol groups. The essential features of the structure of desferrichrome are very similar. There is a cyclic hexapeptide backbone to which are appended three hydroxamate groups. In contrast, the linear trihydroxamate desferrioxamine B has three hydroxamate groups arranged on a linear chain.
In spite of th~se apparently large differences in ligand structure, the iron coordination sites of ferrichrome and ferrioxamine Bare essentially identical and their vis-uv spectra are indistinguishable. Thus in the siderophores, where the major driving force of the reaction is the large .
--enthalpy change associated with the acid-base neutralization in the metal coordination, it is the ability to form the required coordination cavity rather than its pre-formation which is important.
While 
Synthesis of Actinide(IV)-Specific Complexing Agents
We have seen that, while there is a need for strong complexing agents which are relatively specific for plutonium(IV) and the other actinide ions, the presently used complexing agents such as DTPA are relatively nonspecific and thus do not satisfy this criterion. A rational approach to the synthesis of complexing agents specific for Pu(IV) has been based on the following points:
1. Plutonium(IV) i~ chemically similar to iron(III) and has similar biological transport and distribution properties in mammals.
2. The most powerful naturally-occurring sequestering agents which are specific for iron(III) are produced by microbes. The strongest of these is the tricatecholate ligand called I enterobactin. In order to determine the preferred coordination geometry for tetracatecholato complexes of actinide(IV) ions when no geometric constraints are placed on the ligand structure, a series of M(cat) 4 4 -complexes (cat= catecholate dianion) were prepared and stru_cturally characterized. 8
These structures showed a roughly tetrahedral distribution of the catecholate groups around the metal ion with the eight-coordinate geometry very close to the o 2 d symmetry of the tri gena 1-faced .. dodecahedron.
From molecular models a series of compounds which contained four catecholate ligands appended to a backbone molecular framework were prepared. The synthesis of one series of these compounds is shown in Figure 6 . The sulfonated derivatives were found, through animal tests, to be effective plutonium removal agents but also had a singificant toxicity at the administered dose rates. 1 ,S Substitution of the catecholate rings by groups such as sulfonate is required, since the neutral catecholate groups of the 2,3-dihydroxybenzoyl containing ligands tend to have very low water solubility, are relatively unstable to air oxidation, and have an acidity too low to maintain metal complexation under weak acid conditions. As an alternative to sulfonate substitution, carboxylate derivatives. were prepared as shown in Figure 7 . These compounds have eliminated the toxic side effects observed with the sulfonated derivatives while maintaining their effectiveness. The effectiveness of 3,4,3-LICAMC (see Table III and Figure 7 ) have been measured using mice as test animals and a protocol in which a small amount of 238 Pu(IV) citrate is injected, followed one hour later (for the non-control group)
by injection of the chelating agent in saline solution and sacrifice of the animals after 24 hours for an evaluation of plutonium removal. Under these conditions only 6.4% of the administered plutonium would naturally be eliminated by the animal in urine feces. In contrast, 75% of the plutonium was eliminated when the chelating agent was administered. 5
This is a substantially larger amount of plutonium removal for these ligand concentrations than has been seen in other chelating agents 
